Levosimendan Reig Jofre

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Reig Jofre (Levosimendan)

Q: What is Levosimendan Reig Jofre used for?

Levosimendan Reig Jofre is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure and severe chronic heart failure when standard therapies are inadequate. It may also be used off‑label in cardiogenic shock to support circulation.

Q: How does levosimendan work in the body?

Levosimendan enhances cardiac contractility by binding to troponin C, increasing its sensitivity to calcium without raising intracellular calcium concentrations. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that reduces cardiac after‑load and improves overall heart performance.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Typically, a loading dose followed by a continuous infusion is used, but exact amounts and duration must be individualized by a qualified healthcare professional.

Q: Is levosimendan safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by the treating physician.

Q: How do I order Levosimendan Reig Jofre from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does levosimendan compare with other inotropes?

Unlike traditional inotropes that increase intracellular calcium and may raise oxygen demand, levosimendan sensitizes the heart to existing calcium, improving contractility with less metabolic stress. It also provides vasodilation, which can reduce after‑load, offering a distinct hemodynamic profile compared with agents such as dobutamine or milrinone.

Q: What are the storage requirements for Levosimendan Reig Jofre?

Levosimendan Reig Jofre should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the product or shake the vial, as this may affect solution stability.

Q: How is Levosimendan administered?

Levosimendan is administered intravenously. After reconstitution, a typical protocol includes a loading infusion over 10 minutes followed by a continuous infusion for up to 24 hours, but the exact administration schedule is set by the treating physician based on patient needs.

Q: What are the most serious risks associated with levosimendan?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of sudden cardiac death. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout therapy.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with uncontrolled severe hypotension (systolic BP < 90 mmHg) and should be used with caution in those with significant arrhythmias, severe renal or hepatic impairment, or known hypersensitivity to the drug or its excipients.

Levosimendan, the active ingredient in Levosimendan Reig Jofre, is a calcium sensitizer (inodilator) presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and severe chronic heart failure when standard therapies are insufficient.

GNH India supplies Levosimendan Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Laboratorio Reig Jofre, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in cardiovascular care to improve cardiac performance in specific heart‑failure states.
Acute decompensated heart failure: enhances cardiac output and relieves congestion.
Severe chronic heart failure: provides hemodynamic support when conventional treatment fails.
Cardiogenic shock (off‑label): may stabilize circulation in refractory shock cases.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, which together improve overall cardiac performance.

Side Effects

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

Hypotension: drop in blood pressure, especially after loading dose.
Headache: mild to moderate intensity.
Nausea or vomiting: gastrointestinal discomfort.
Tachycardia: increased heart rate.
Flushing: warm sensation and reddening of skin.
Arrhythmias: occasional premature beats.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain due to reduced coronary perfusion.
Allergic reactions: rash, pruritus, or anaphylaxis.
Sudden cardiac death: rare but reported in high‑risk patients.
Hepatic dysfunction: elevated liver enzymes in some cases.

Precautions & Warnings

Before initiating levosimendan, clinicians should consider several safety measures.
Monitor blood pressure: watch for excessive hypotension.
Observe cardiac rhythm: detect arrhythmias promptly.
Adjust concomitant vasodilators: reduce dose of other blood‑pressure‑lowering agents.
Use cautiously in renal or hepatic impairment: dose may need modification.
Contraindicated in severe hypotension: avoid if systolic BP < 90 mmHg.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid)

Potent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma levels.
Other inotropes that raise intracellular calcium (e.g., dobutamine): raise risk of arrhythmias.

Moderate Interactions (Monitor Closely)

Diuretics: may enhance blood‑pressure‑lowering effect.
Beta‑blockers: could blunt therapeutic response.
ACE inhibitors or ARBs: additive hypotensive effect.
Anticoagulants: monitor for increased bleeding tendency.

Frequently Asked Questions

Levosimendan Reig Jofre is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure and severe chronic heart failure when standard therapies are inadequate. It may also be used off‑label in cardiogenic shock to support circulation.

Levosimendan enhances cardiac contractility by binding to troponin C, increasing its sensitivity to calcium without raising intracellular calcium concentrations. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that reduces cardiac after‑load and improves overall heart performance.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Typically, a loading dose followed by a continuous infusion is used, but exact amounts and duration must be individualized by a qualified healthcare professional.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional inotropes that increase intracellular calcium and may raise oxygen demand, levosimendan sensitizes the heart to existing calcium, improving contractility with less metabolic stress. It also provides vasodilation, which can reduce after‑load, offering a distinct hemodynamic profile compared with agents such as dobutamine or milrinone.

Levosimendan Reig Jofre should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the product or shake the vial, as this may affect solution stability.

Levosimendan is administered intravenously. After reconstitution, a typical protocol includes a loading infusion over 10 minutes followed by a continuous infusion for up to 24 hours, but the exact administration schedule is set by the treating physician based on patient needs.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of sudden cardiac death. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout therapy.

Levosimendan is contraindicated in patients with uncontrolled severe hypotension (systolic BP < 90 mmHg) and should be used with caution in those with significant arrhythmias, severe renal or hepatic impairment, or known hypersensitivity to the drug or its excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.